1-3 of 3
Annika Pasanen
Close
Sort by
Journal Articles

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial

Clinical Trials & Observations
Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppä, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius
Journal: Blood Advances
Blood Adv (2024) 8 (2): 407–415.
https://doi.org/10.1182/bloodadvances.2023011920
Published: 2024
Includes: Supplemental data
Journal Articles

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma

Clinical Trials & Observations
Leo Meriranta, Annika Pasanen, Amjad Alkodsi, Jari Haukka, Marja-Liisa Karjalainen-Lindsberg, Sirpa Leppä
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3742–3753.
https://doi.org/10.1182/bloodadvances.2020001727
Published: 2020
Includes: Supplemental data
Journal Articles

Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series

Jillian F. Wise, Sigve Nakken, Chloé B. Steen, Daniel Vodák, Gunhild Trøen, Bjarne Johannessen, Ole Christian Lingjærde, Vera Hilden, Yngvild Nuvin Blaker, Baoyan Bai, Lars Birger Aasheim, Annika Pasanen, Susanne Lorenz, Anita Sveen, Ragnhild A. Lothe, Ola Myklebost, Sirpa Leppä, Leonardo A. Meza-Zepeda, Klaus Beiske, Michael S. Lawrence, Eivind Hovig, June Helen Myklebust, Erlend B. Smeland, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1859–1866.
https://doi.org/10.1182/bloodadvances.2019001325
Published: 2020
Includes: Supplemental data